Rainer J. Klement, N. Abbasi-Senger, S. Adebahr, H. Alheid, M. Allgaeuer, G. Becker, O. Blanck, J. Boda-Heggemann, T. Brunner, M. Duma, M. J. Eble, I. Ernst, S. Gerum, D. Habermehl, P. Hass, C. Henkenberens, G. Hildebrandt, D. Imhoff, H. Kahl, N. D. Klass, R. Krempien, V. Lewitzki, F. Lohaus, C. Ostheimer, A. Papachristofilou, C. Petersen, J. Rieber, T. Schneider, E. Schrade, R. Semrau, S. Wachter, A. Wittig, M. Guckenberger, N. Andratschke

• Background The aim of this analysis was to model the effect of local control (LC) on overall survival (OS) in patients treated with stereotactic body radiotherapy (SBRT) for liver or lung metastases from colorectal cancer. Methods The analysis is based on pooled data from two retrospective SBRT databases for pulmonary and hepatic metastases from 27 centers from Germany and Switzerland. Only patients with metastases from colorectal cancer were considered to avoid histology as a confounding factor. An illness-death model was employed toBackground The aim of this analysis was to model the effect of local control (LC) on overall survival (OS) in patients treated with stereotactic body radiotherapy (SBRT) for liver or lung metastases from colorectal cancer. Methods The analysis is based on pooled data from two retrospective SBRT databases for pulmonary and hepatic metastases from 27 centers from Germany and Switzerland. Only patients with metastases from colorectal cancer were considered to avoid histology as a confounding factor. An illness-death model was employed to model the relationship between LC and OS. Results Three hundred eighty-eight patients with 500 metastatic lesions (lung n = 209, liver n = 291) were included and analyzed. Median follow-up time for local recurrence assessment was 12.1 months. Ninety-nine patients with 112 lesions experienced local failure. Seventy-one of these patients died after local failure. Median survival time was 27.9 months in all patients and 25.4 months versus 30.6 months in patients with and without local failure after SBRT. The baseline risk of death after local failure exceeds the baseline risk of death without local failure at 10 months indicating better survival with LC. Conclusion In CRC patients with lung or liver metastases, our findings suggest improved long-term OS by achieving metastatic disease control using SBRT in patients with a projected OS estimate of > 12 months.…